Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX®
From Exelixis (EXEL) we learned that its partner, Ipsen Biopharmaceuticals Canada, has received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for the treatment of hepatocellular . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.